MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
HOUSTON ― The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for ...
